Johnson & Johnson and Bayer’s new blockbuster-Xarelto, a heart disease drug


Xarelto, the clot prevention drug jointly owned by Bayer AG and Johnson & Johnson, was shown to significantly cut the risk of stroke, heart attack, amputation or death for patients with severe atherosclerosis, or blockage in the arteries. Patients who took Xarelto in combination with aspirin experienced a 24% decline in those serious events, compared with patients who…Full link